2683 studies found for:    "Prostatic Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
Conditions: Adenocarcinoma of the Prostate;   Bone Metastases;   Soft Tissue Metastases;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Intervention: Drug: Ranolazine
22 Active, not recruiting
Has Results
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Conditions: Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Biological: sargramostim;   Biological: recombinant vaccinia-TRICOM vaccine;   Biological: fowlpox-PSA-TRICOM vaccine;   Drug: bicalutamide;   Drug: goserelin acetate
23 Completed
Has Results
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis
24 Unknown  Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
Conditions: Cancer of the Prostate;   Prostate Cancer;   Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E;   Drug: Placebo
25 Terminated
Has Results
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
Conditions: Prostate Cancer;   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: sunitinib malate;   Drug: docetaxel;   Drug: prednisone
26 Active, not recruiting Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: prednisone
27 Recruiting Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Conditions: Prostate Cancer;   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: vorinostat;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography/computed tomography
28 Completed Perifosine in Treating Patients With Recurrent Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: perifosine;   Other: laboratory biomarker analysis
29 Recruiting Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Prostate Cancer;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis;   Other: questionnaire administration;   Drug: doxorubicin-GnRH agonist conjugate AEZS-108
30 Terminated Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: motexafin lutetium;   Drug: photodynamic therapy
31 Not yet recruiting Magnetic Resonance Guided Focal Stereotactic Radiosurgery in Treating Patients With Low- or Intermediate-Risk Localized Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Radiation: stereotactic radiosurgery;   Procedure: magnetic resonance imaging;   Other: quality-of-life assessment;   Procedure: Serum Prostate Antigen Test;   Procedure: Digital Rectal Exam;   Behavioral: Expanded Prostate Cancer Index Composite
32 Active, not recruiting Genistein in Treating Patients With Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage II Prostate Cancer;   Stage III Prostate Cancer
Interventions: Dietary Supplement: genistein;   Other: placebo;   Procedure: therapeutic conventional surgery
33 Recruiting High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Conditions: Prostate Cancer;   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Radiation: Brachytherapy;   Radiation: Stereotactic Body Radiation Therapy;   Procedure: Quality-of-life assessment;   Other: Questionnaire administration
34 Withdrawn Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Radiation: brachytherapy;   Radiation: image-guided radiation therapy;   Other: laboratory biomarker analysis
35 Recruiting Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Goserelin acetate;   Drug: Leuprolide acetate;   Radiation: Radiation therapy
36 Completed Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
Conditions: Hormone-refractory Prostate Cancer;   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Prostate Cancer;   Recurrent Prostate Cancer
Intervention: Drug: Dasatinib
37 Recruiting Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
Conditions: Adenocarcinoma of the Prostate;   Stage I Prostate Cancer;   Stage II Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Dietary Supplement: cholecalciferol;   Drug: placebo administration;   Other: active surveillance;   Other: laboratory biomarker analysis
38 Active, not recruiting Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis
39 Active, not recruiting Sipuleucel-T Manufacturing Demonstration Study
Conditions: Cancer of Prostate;   Cancer of the Prostate;   Neoplasms, Prostate;   Neoplasms, Prostatic;   Prostate Cancer;   Prostate Neoplasms;   Prostatic Cancer
Intervention: Biological: sipuleucel-T
40 Active, not recruiting Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Drug: vorinostat;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years